EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparison of accelerated and standard infliximab induction regimens in acute severe ulcerative colitis using propensity score analysis: a retrospective multicenter study in China

Xinyu Liu iD, Hui Li iD, Feng Tian, Ying Xie, Xiaoqi Zhang, Min Zhi, Min Zhang, Xiaomei Song, Hong Guo iD, Xiaofei Li, Jie Liang, Jun Shen und 1 weitere

Gastroenterology Report · 22.12.2023 · 12

DOI: 10.1093/gastro/goae051 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gastroenterology Report, online erschienen am 07.06.2024. Verfasst von Xinyu Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, P.…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National High Level Hospital Clinical Research Funding, CAMS Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The optimal regimen of infliximab salvage in acute severe ulcerative colitis (ASUC) patients remains controversial. This study aimed to compare accelerated and standard infliximab induction in Chinese ASUC patients, and to explore risk factors and concrete accelerated regimens for them.

Methods

Data were retrospectively collected from steroid-refractory ASUC patients receiving infliximab as rescue therapy at seven tertiary centers across China. Outcomes including colectomy and clinical remission (Mayo score ≤ 2 and every subscore ≤ 1 at Day 14) rates were compared between patients receiving accelerated and standard infliximab induction using propensity score adjustment for potential confounders. The dose–response relationship was explored by plotting restricted cubic splines. Logistic regression and Cox proportional hazards regression analyses were performed to determine risk factors for adverse outcomes. A systematic review and meta-analysis was also performed.

Results

A total of 76 patients were analysed: 29 received standard and 47 received accelerated induction. The accelerated group had a higher 90-day colectomy rate (17.8% vs 0%, P = 0.019) and lower clinical remission rate (27.7% vs 65.5%, P = 0.001). After adjusting for propensity score and institution, there was no significant difference in colectomy or clinical remission rates (both P > 0.05). Dose–effect curves showed decreased colectomy hazard with higher cumulative infliximab dosage within 5 days, with no improvement observed for increasing cumulative infliximab dosage within 28 days. Multivariate logistic regression analyses revealed C-reactive protein of >10 mg/L at infliximab initiation (odds ratio = 5.00, 95% confidence interval: 1.27–24.34) as an independent risk factor for no clinical remission. Meta-analysis also revealed no significant difference in colectomy rates at 3 months (P = 0.54).

Conclusions

After adjusting for confounders, there were no significant differences in colectomy or clinical remission rates between accelerated and standard infliximab induction among ASUC patients. Early administration of an intensified dosage within 5 days may be beneficial. Elevated C-reactive protein at infliximab initiation indicated need for intensive treatment.

Schlagwörter

Stichwörter der Autor:innen

accelerated inductionacute severe ulcerative colitisinfliximabpropensity score analysis

Autor:innen und Institutionen

  • Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, P. R. China.
  • Eight-Year Medical Doctor Program, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, P. R. China.
  • Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, P. R. China.
  • Department of Gastroenterology, Nanjing Drum Tower Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu, P. R. China.
  • Department of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.
  • Department of Gastroenterology, Chongqing General Hospital, Chongqing, P. R. China.

ORCID-Profile: Xinyu Liu, Hui Li, Hong Guo

Förderung

  • National High Level Hospital Clinical Research Funding
  • CAMS Innovation Fund for Medical Sciences

Zitieren

APA

Liu, X., Li, H., Tian, F., Xie, Y., Zhang, X., Zhi, M., Zhang, M., Song, X., Guo, H., Li, X., Liang, J., Shen, J., & Li, Y. (2023). Comparison of accelerated and standard infliximab induction regimens in acute severe ulcerative colitis using propensity score analysis: a retrospective multicenter study in China. Gastroenterology Report, 12. https://doi.org/10.1093/gastro/goae051

Vancouver

Liu X, Li H, Tian F, Xie Y, Zhang X, Zhi M, et al. Comparison of accelerated and standard infliximab induction regimens in acute severe ulcerative colitis using propensity score analysis: a retrospective multicenter study in China. Gastroenterology Report. 2023;12. doi:10.1093/gastro/goae051

BibTeX
@article{Liu2023,
  author = {Liu, Xinyu and Li, Hui and Tian, Feng and Xie, Ying and Zhang, Xiaoqi and Zhi, Min and Zhang, Min and Song, Xiaomei and Guo, Hong and Li, Xiaofei and Liang, Jie and Shen, Jun and Li, Yue},
  title = {Comparison of accelerated and standard infliximab induction regimens in acute severe ulcerative colitis using propensity score analysis: a retrospective multicenter study in China},
  journal = {Gastroenterology Report},
  year = {2023},
  volume = {12},
  doi = {10.1093/gastro/goae051}
}
Kostenlos starten →